60 Degrees Pharmaceuticals (SXTP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SXTP 60 Degrees Pharmaceuticals

Watchlist

1.320
+0.160+13.79%

Close Dec 24 13:00 ET

1.260
-0.060-4.55%

Post 16:12 ET

3.03MMarket Cap-0.41P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral
BenzingaDec 23 11:58 ET
60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment
MT NewswiresDec 23 09:39 ET
Express News | Sixty Degrees Pharmaceuticals And Tufts Medical Center Sign Patent License Agreement To Develop Tafenoquine For Babesiosis Treatment And Prevention; 60 Degrees Gains Exclusive Commercialization Rights With Revenue Sharing And Joint Patent Ownership...
BenzingaDec 23 08:58 ET
Express News | 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
ReutersDec 11 08:56 ET
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
BenzingaDec 11 05:27 ET
Trending Stocks Today | 60 Degrees Pharmaceuticals Shoots up 31.27% Post-Market
Moomoo NewsDec 10 17:00 ET

Comments

flabbyduck

Dec 23 07:59

nice quick small trading (:
$60 Degrees Pharmaceuticals (SXTP.US)$

Share Your Profit/Loss

Jaguar8

Dec 23 07:57

NEWS

$60 Degrees Pharmaceuticals (SXTP.US)$
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
Monday, 23rd December at 8:57 am
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW)) ("60 Degrees" or the "Company"), pharmaceutical company, and Tufts Medical Center ("Tufts MC"), a leading academic medical center, today announced the signi...

broke ask

Dec 17 12:28

$60 Degrees Pharmaceuticals (SXTP.US)$ 🙏 moon 🙏

Jaguar8

Dec 11 07:56

NEWS

$60 Degrees Pharmaceuticals (SXTP.US)$
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
Wednesday, 11th December at 8:56 am
• The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.
• The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.
• The double-blind, placebo-controlled trial will examine ou...